TRIANEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIANEX (TRIANEX).
Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
| Metabolism | Primarily hepatic via CYP3A4; undergoes reduction and conjugation to inactive metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites. |
| Half-life | Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment. |
| Protein binding | 98% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (range 0.7–0.9 L/kg), indicating extensive extravascular distribution with high tissue affinity. |
| Bioavailability | Oral: 45% (range 40–50%) due to first-pass metabolism; IM: 100%. |
| Onset of Action | Oral: 30–60 minutes; IV: 5–10 minutes; IM: 15–30 minutes based on time to measurable serum concentrations. |
| Duration of Action | Oral: 6–8 hours; IV: 4–6 hours; clinical effect correlates with serum levels >0.5 μg/mL. |
| Molecular Weight | 434.5 Da |
50 mg orally once daily.
| Dosage form | OINTMENT |
| Renal impairment | eGFR 30-89 mL/min: 50 mg every other day; eGFR <30 mL/min: 25 mg every other day. |
| Liver impairment | Child-Pugh A: 50 mg daily; Child-Pugh B: 25 mg daily; Child-Pugh C: not recommended. |
| Pediatric use | 1 mg/kg orally once daily (max 50 mg). |
| Geriatric use | Start at 25 mg orally once daily; titrate based on tolerability. |
| 1st trimester | Triamcinolone is a corticosteroid; use in first trimester may be associated with a small increased risk of oral clefts. Use only if clearly needed and after considering safer alternatives. |
| 2nd trimester | Use with caution; potential for fetal growth restriction and adrenal suppression with prolonged or high-dose exposure. Short courses may be considered if benefits outweigh risks. |
| 3rd trimester | High doses near term may cause neonatal adrenal suppression. Avoid unless necessary for maternal condition. |
Clinical note
Comprehensive clinical and safety monograph for TRIANEX (TRIANEX).
| Placental transfer | Triamcinolone crosses the placenta. The degree of transfer is moderate; it is metabolized by placental 11β-HSD2, but to a lesser extent than prednisolone and methylprednisolone, resulting in higher fetal exposure. |
| Breastfeeding | Triamcinolone is excreted into breast milk in small amounts. The American Academy of Pediatrics considers it compatible with breastfeeding. However, high maternal doses may suppress infant's adrenal function. Monitor infant for growth and adrenal effects if mother requires prolonged high doses. |
■ FDA Black Box Warning
Corticosteroids may increase risk of infections, mask signs of infection, and cause adrenal suppression. Avoid live vaccines. Do not administer via epidural or intrathecal routes due to risk of serious neurologic events.
| Serious Effects |
Systemic fungal infectionKnown hypersensitivity to triamcinolone or any component of the formulationIntrathecal administration (contraindicated due to safety concerns)Administration of live or live-attenuated vaccines (with immunosuppressive doses)
| Precautions | Adrenal suppression with prolonged use, Increased susceptibility to infections, Osteoporosis and bone necrosis, Gastrointestinal perforation, especially in patients with inflammatory bowel disease, Cushing's syndrome with high doses, Glaucoma and cataracts with ophthalmic use, Hypothalamic-pituitary-adrenal axis suppression, Impaired wound healing |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase systemic exposure. Limit high-sodium foods to reduce fluid retention. Potassium-rich foods (bananas, oranges) may be needed to counteract hypokalemia; monitor potassium levels. Avoid alcohol as it may increase gastrointestinal irritation. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | First trimester: Risk of neural tube defects and cardiac malformations based on animal studies; human data limited. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and potential neurodevelopmental effects. Avoid use unless benefits outweigh risks. |
| Fetal Monitoring | Baseline and serial fetal ultrasound for growth and anatomy. Regular assessment of maternal blood pressure, renal function, and hepatic enzymes. Nonstress test or biophysical profile after 28 weeks in high-risk cases. |
| Fertility Effects | Animal studies show impaired fertility and embryotoxicity at supratherapeutic doses. Human data insufficient; theoretical risk of reversible menstrual irregularities and reduced sperm quality in males. |
| Clinical Pearls | TRIANEX (triamcinolone) is a potent corticosteroid; use lowest effective dose and shortest duration to minimize systemic side effects. Avoid abrupt withdrawal after prolonged therapy. Monitor for signs of adrenal suppression, osteoporosis, and immunosuppression. For intra-articular injection, limit frequency to every 3-4 weeks per joint to avoid cartilage damage. Inhaled forms require mouth rinsing after use to prevent oral candidiasis. |
| Patient Advice | Do not stop taking this medication suddenly; follow your doctor's tapering instructions. · Take with food or milk to reduce stomach upset if using oral tablets. · Report any signs of infection (fever, sore throat) or unusual bleeding/bruising. · Avoid live vaccines while on this medication. · Use inhaled form exactly as prescribed; rinse mouth with water after each use to prevent thrush. |